The revised EBM catalog came into force in Germany In October 2020

22

Oct 2020

The revised EBM (German Uniform Evaluation Standard) catalog came into force on October 1, 2020. MTRC has compiled the selection of the most significant changes.

The reimbursement of services in the public outpatient sector in Germany is regulated in the EBM catalogue (Einheitlicher Bewertungsmaßstab), updated once in a quarter (4 times a year). The adaption time frame of the EBM catalogue for a specific code is around five years but varies depending on the evidence.

The list of the most important changes in EBM for the fourth quarter of 2020 is presented below:

  • In-vitro diagnostics
    • GOP 32779 “SARS-CoV-2” for the antigen testing for the detection of SARS-CoV-2 with a tariff of €10.80 was added
    • GOP 32867 “Genotyping for determination of the dihydropyrimidine dehydrogenase (DPD) metabolism status prior to systemic therapy with 5-fluorouracil or its precursors according to the summary of product characteristics (information for healthcare professionals)” with a tariff of €120 was added
  • Telemedicine
    • GOP 01670 “Surcharge in connection with the insured, basic or consulting flat rate for obtaining a teleconsultation” with a tariff of €12.09 was added
    • GOP 01671 “Assessment of a medical problem via the teleconsultation” with a tariff of €14,06 was added
    • GOP 01672 “Surcharge for the fee order item 01671 for the continuation of the assessment via the teleconsultation” with a tariff of €7.14 per each further five (5) minutes up to three (3) times in case of treatment was added
  • Vacuum wounds therapy
    • GOP 02314 “Additional flat rate for vacuum therapy for the intended secondary wound closure according to No. 33 of Annex I "Recognized examination or treatment methods" of the Guideline Methods for Outpatient Medical Care of the Federal Joint Committee” with a tariff of €14.83
    • GOP 31401 “Surcharge for an intervention under the Section 31.2 for the application of a system for vacuum therapy for the intended primary wound closure in accordance with No. 33 of Annex I "Recognized examination or treatment methods" of the Guideline Methods for Outpatient Medical Care of the Federal Joint Committee” with a tariff of €7.47 was added
    • GOP 36401 “Surcharge for an intervention under the Section 36.2 for the application of a system for vacuum therapy for the intended primary wound closure in accordance with No. 33 of Annex I "Recognized examination or treatment methods" of the Guideline Methods for Outpatient Medical Care of the Federal Joint Committee” with a tariff of €7.03.

The latest version of EBM can be accessed here.

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more